Neurol. praxi. 2012;13(3):155-158

Adherence to treatment in multiple sclerosis

MUDr.Pavel Hradílek, Ph.D.
MS centrum, Neurologická klinika FN Ostrava

According to Health Organization (WHO) adherence is defined as the extent to which the patients behaviour – taking medication, following

a diet, and/or executing lifestyle changes – corresponds with agreed recommendations from a healthcare provider. High level of adherence

is necessary in the treatment of chronic diseases. Following article deals with adherence in the treatment of multiple sclerosis, especially

focusing on the disease modifying drugs of first choice, that are all injections, and need to be taken long term and regularly. Some methods,

how to measure adherence are discussed, as well as factors leading to non-adherence and some recommendations how to increase adherence.

It is necessary to support adherence all the time in everyday clinical practice. Increasing the effectiveness of adherence interventions

may have a far greater impact on the health of the population than any improvement in specific medical treatments.

Keywords: multiple sclerosis, adherence, disease modifying drugs, injections

Published: May 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hradílek P. Adherence to treatment in multiple sclerosis. Neurol. praxi. 2012;13(3):155-158.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, The Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outtcomes, 2004; 2: 12. Go to original source... Go to PubMed...
    2. Brandes DW, Callender T, Lathi E, O´Leary S. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin, 2009; 25: 77-92. Go to original source... Go to PubMed...
    3. Cohen B. Adherence to disease modifying therapy for multiple sclerosis. Int J MS Care 2006; 8: 32-37.
    4. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007; 61: 1922-1930. Go to original source... Go to PubMed...
    5. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung HP, Seeldrayers P, Soelberg S?rensen P, Rovaris M, Martinelli V, Hommes OR and the Early Treatment of MS Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis; a randomised study".Lancet 2001; 357: 1576-1582. Go to original source... Go to PubMed...
    6. Comi G, Martinelli V, Rodegher M, Moiola M, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M for the PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. The Lancet, Volume 374, Issue 9700, Pages 2009; 31: 1503-1511. Go to original source... Go to PubMed...
    7. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006; 38(3): 167-171. Go to original source... Go to PubMed...
    8. Cramer JA, Cuffel BJ, Divan V, Al-Sabbaqh A, Glassman M. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006; 113(3): 156-162. Go to original source... Go to PubMed...
    9. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW and the CHAMPS Study Group. Intramuscular Interferon Beta-1A Therapy Initiated durmng a First Demyelinating Event in Multiple Sclerosis. N Engl J Med 2000; 343: 898-904. Go to original source... Go to PubMed...
    10. Haynes RB, et al. Cochrane Database Syst Rev 2005; (4): CD000011.
    11. Horne R. Compliance, adherence and concordance: implications for asthma treatment. Chest 2006; 130(Suppl 1): 65-72. Go to original source... Go to PubMed...
    12. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R and for the BENEFIT Study Group. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249. Go to original source... Go to PubMed...
    13. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self inject. Ann Behav Med 2001; 23(2): 125-132. Go to original source... Go to PubMed...
    14. O´Brien JA, Ward AJ, Patrick AR. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003; 3: 17. Go to original source... Go to PubMed...
    15. Sabaté E, et al. Adherence to Long-term therapies: evidence for action. Geneva, Switzerland: Health organization, 2003.
    16. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to Interferons in the treatment of multiple sclerosis. A Non-Experimental, Retrospective, Cohort Study. Clin Drug Investig 2010; 30(2): 89-100. Go to original source... Go to PubMed...
    17. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001; 33(6): 865-872. Go to original source... Go to PubMed...
    18. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes R, Kaufman Ch, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, Stüve O, Racke M, Frohman EM. Factors that influence adherence with diseasemodifying therapy in MS. J Neurol 2009; 256: 568-576. Go to original source... Go to PubMed...
    19. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 6(4): 551-554. Go to original source... Go to PubMed...
    20. Zapletalová O. Léčba časných stadií roztroušené sklerózy mozkomíšní. Remedia 2009; 19: 198-204.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.